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Malaria infection kills more than one million human every year, mainly under-5-year-old children, including in 
South East Asian nations. Gamma radiation given at a single dose is commonly used to create the attenuated 
Plasmodium parasites to get vaccine materials. However, there is no study on the infectivity of parasites after 
fractionated γ-radiation. This study aimed to assess the infectivity of parasites after irradiated with fractionated 
γ-rays in mice. A number of Plasmodium berghei that was irradiated in two fractions of 100 and 50 Gy, 100 and 
75 Gy; and 100 and 100 Gy within 5 minutes of interval time was injected intraperitoneally into 12 mice. Mice 
injected with unirradiated parasites (0 Gy) served as a control group. The parasitemia level of intraerythrocytic 
parasites in each group was observed at days post injection up to 20 days by making Giemsa stained thin blood 
smears and observed under the microscope. Results showed that fractionation radiation did not effectively 
attenuate the parasites where they still grew in blood of mice, except for 100+75 Gy. There are no significant 
differences among the treatment groups (p>0.05). This is different from irradiation at the single dose that 
resulted in almost completely attenuated parasites mainly the dose of 150 Gy. This implicating that irradiation 
of gamma rays at a single dose is a better way to mitigate parasites than fractionation dose as the infectivity of 
irradiated parasites were lower compared to that of fractionated dosage. 
 





Malaria is a protozoan infection with protean manifestations in the human, cause more than 
one million mortalities per year mainly children under five years old, especially in Africa (Ramani S et 
al., 2016). Approximately 50% of the world’s population is very susceptible to malaria; for example, in 
2017, there were an estimated 219 million cases of malaria in 87 countries (WHO, 2018). Even 
though decades of intense efforts to control human malaria, the disease is still one of the significant 
health problems in Africa and parts of South East Asia counties. The successful in eradicating P. 
falciparum malaria worldwide will almost certainly require the development of an efficacious vaccine 
that includes a blood-stage (intraerythrocytic) component (Feachem et al., 2010). Gamma radiation is 
an effective method used to generate the whole parasite-based malaria vaccines (Seo, 2015; Oakley et 
al., 2013; Mahmoudi and Keshavarz, 2018). 
Ionizing radiation is harmful to the growth and survival of parasites. By using murine models, 
it is known that asexual blood-stage parasites exposed to high doses of gamma rays failed to induce 
blood-stage parasite infection (Gerald, 2011), and injection of radiation-attenuated blood stage 
parasites adequately protected against parasitemia (Gerald, 2011; Bijker et al., 2015; Ouattara and 
Laurens, 2015) and cerebral malaria (Gerald, 2011). More than two decades ago, researchers had 
RESEARCH PAPER 
Aceh Journal of Animal Science, 4(1): 18-26 












found that volunteers built up high levels of protection to malaria after being bitten by mosquitoes 
containing radiation-weakened parasites in its salivary glands. Since then, they had been striving to 
utilize vaccines made from whole living parasites. To ensure that the parasites are sufficiently 
weakened for the vaccine, they must be exposed to a radiation dose of at least 150 Gray of gamma 
rays (dose rate of 300-350 Gy h-1), but not more (Anonymous, 2007; Syaifudin et al., 2011). 
The dose-response relationship of biological parameters following exposure to ionizing 
radiation is affected by some factors. Of these, the most important are the target cells under study, 
dose range, dose rate and dose spacing (fractionation), as well as the temporal relationship of the 
change and the strain of organism utilized (Hall and Brenner, 1991). In vaccine development, 
irradiation is usually conducted at once (single dose) that may kill parasites and so live-attenuated 
parasites are not obtained for vaccine materials. One alternative to overcome this case is dividing the 
doses of irradiation into two or more parts (fractionation) at a lower dose than killing dose.  
Exposure to ionizing radiation has a severe effect on the viability and further proliferation of 
living cells (Cabiscol et al., 2000; Mettler and Voelz, 2002). All tissues exhibit varying degrees of 
susceptibility to ionizing radiation. Each has a threshold that, if crossed, will produce irreversible 
damage. Fractionation was discovered early in the 20th century that a more substantial total radiation 
dose can be delivered if divided over several treatments/fractions, than when a single dose is given. 
This is so because the organism's tissues get a chance to recover between treatments (Fulda et al., 
2010; Han and Yu, 2009). Protracted and fractionated doses cause less effect allowing time for 
intracellular repair and tissue recovery (Moding et al., 2013). In this case, the live-attenuated parasites 
are intended to be used as vaccine materials.  
For a long time, the laboratory mouse has been widely used for malaria vaccine research 
where the pathogen under study is intractable to routine laboratory manipulation. However, the 
experimental study of the human malaria parasite P. falciparum is particularly problematic due to the 
fact that its complete life cycle cannot be maintained in vitro. Thus rodent models of malaria such as P. 
berghei have been used successfully to complement research on P. falciparum (Carlton et al., 2002).  
A serial research on malaria vaccine had been done in the Center where the main focus, 
according to tasks, is the determination of dose and dose rate of gamma rays that is most effective in 
attenuating P. berghei, either for pre-erythrocytic- or erythrocytic-stage malaria parasites (Syaifudin et 
al., 2011; Syaifudin et al., 2013). These are considered by several aspects such as hematopoietic, 
histopathologic, immunologic and genetics. In hematopoietic point of view, an effective single dose 
of gamma rays had been obtained (150 Gy) at a dose rate of 380 Gyh-1. However, this high dose of 
radiation delivered as a single treatment to the mice is risky as the low number of attenuated parasites. 
To get broader insight, this paper describes the results on the infectivity of irradiated P. berghei in 
mice, the most appropriate model, after fractionated exposure of gamma rays. Hence, the objective of 
the present study was to assess the infectivity of parasites after irradiated with fractionated γ-rays in mice 
 
 
MATERIALS AND METHODS 
 
Parasite and animal model  
Mouse blood infected with Plasmodium berghei (Antwerpen-Kasapa, ANKA strain) at the 
density of ±106 parasites ml-1 were obtained from Eijkman Institute for Molecular Biology, 
Indonesian Ministry of Research and Technology. Male Swiss-Webster mice (6–8 weeks old at the 
beginning of experimental study) were purchased from Tropical Medicine Laboratory, National 
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Institute of Health Research and Development, Ministry of Health and were housed in animal room 
of the Center for Technology of Radiation Safety and Metrology, BATAN and handled according to 
experimental animal standard guidelines. All treatments in this experiment were reviewed and 
approved by the Animal Care and Use National Commission, Institute of Health Research and 
Development, the Ministry of Health. 
 
Experimental design 
The completely randomized design was used in this study. Twelve mice were divided into 
four groups consists of three mice in each. One group was as control, and others group were 
irradiated with gamma rays with dose variation as described in irradiation subsection.  
 
Infection of mice  
Mice were intraperitoneally (IP) injected with parasitized mouse blood containing about 106 P. 
berghei ml-1. Parasitaemia was monitored started in the third day after infection on the blood smears 
after being stained with Giemsa solution using light microscopy and was repeated every 2-3 days up 
to day 20. 
 
Irradiation of intraerythrocytic-stage parasites  
Mouse blood infected bloods with 10-25% parasitemia were put into a 2 mL sterilized vial 
and irradiated in vitro in a gamma irradiator (Cobalt-60 source) of the Center for Application of 
Isotope and Radiation, BATAN to fractionated doses of 0 (non-irradiated), 100+50, 100+75 and 
100+100 Gy at interval time of 5 minutes and at dose rate of 380.0 Gy h-1. Then the irradiated 
parasites were injected intraperitoneally to mice. Mice injected with non-irradiated blood were used as 
control. 
 
Parasitemia observation.  
Parasitemias in infected mouse blood from each group were observed started on day two 
post-injection and repeated every 2-3 days up to 20 days by Giemsa staining. Thin blood smears were 
prepared by tail-end bleeding, room temperature dried, and methanol fixed before staining step that 
was done with a 10% Giemsa solution for 10 minutes. Slides were observed at a 1000× magnification 
(on a drop of oil-immersion) using a light microscope by reading around 20 fields for every slide. The 
total number of red blood cells counted was about 4000 cells for every treatment. 
 
Statistical analysis. 
Statistical analysis on the significant difference between doses of radiation was done using 
software SPSS version 16.0 for Windows. The distribution of data is determined with the 
Kolmogorov-Smirnov test. In case of the normal distribution is obtained then parametric or One-way 
ANOVA test is applied, whereas in case of the not normal distribution is obtained then the Mann-




Results showed that parasitemia was detected in the blood of the mice starting on day 7 after 
injection of irradiated P. berghei except for 100+75 Gy that took longer time (day 9) and reached 
values above 10% by day 11 (Figure 1a). The increment of parasitemia was seen for all days of 
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observation in all treatment groups, mainly 100+50 Gy. All mice developed parasitemia even though 
the parasites had been irradiated with gamma rays and it takes a longer time compared to non-
irradiated parasites, indicating an effect of irradiation on the biological activity of parasites. From day 
9 to 13, parasitemia rose slightly mainly at the dose of 100+75 Gy and was not significantly different 
from other doses (100+50 and 100+100 Gy) (p>0.05). Among the three treatments conducted in this 
experiment, the fractionated dose of 100+75 Gy was most effective in inhibiting the growth of 
parasites in the blood of mice. The survival of mice of 100+50 Gy group was shorter than other 
groups, indicating the failed of fractionated dose in inhibiting the parasite growth. 
In this experiment, an extremely low parasitemia was found in 150 and 175 Gy doses. The 
parasitaemia for dose of 150 Gy was not significantly different (p<0.05) with 175 Gy, but significantly 
different (p=0.029) with both control (0 Gy) and 200 Gy.  Inoculation of non-irradiated (0 Gy) P. 
berghei resulted in a very high infection and all mice were dead on day 17. The mice showed, on days 
5–10 of infection, clinical signs of malaria such as loss of sense and paralysis of the lower half of the 
body. Parasitaemia in this control mice was started to be detected three days after infection and 
divided rapidly for all infected mice up to day 20 of infection.  All mice inoculated with γ-ray 
irradiated parasites at 150 and 175 Gy as a single dose were survived up to the end of the experiment. 
The use of γ-ray irradiated parasites at 150 Gy as one dose revealed a significant decrease immunity 
level compared with their analogous at 100+50 Gy till day 17 or more after injection. Exposure to 
high doses of γ-radiation may cause the attenuation and even mortality of intraerythrocytic P. berghei. 
At three days after treatment with 150 and 175 Gy of γ-radiation, approximately 99.5% reduction in 
parasitemia was observed (Figure 1b). For both radiation doses the parasites still alive or survived and 
had a normal growth indicating they were able to repair the cell damage and then repopulate. These 
were highly different from that of mice injected with 200 Gy irradiated parasites. 
If current results are compared with that of a single dose (once) of irradiation at 150 Gy as an 
optimal dose to attenuate parasites, these three fractionated doses treatments (100+50, 100+75 and 
100+100 Gy) did not effectively inhibit the growth of parasites. Parasites growth (parasitemia) for 
doses of 100+50 and 100+75 Gy were significantly different (p<0.05) with their corresponding single 
doses (150 and 175 Gy), but no significant difference was found between 100+100 and 200 Gy 
(p=0.591). The fractionated dose spares parasites to growth as normal parasites (control, 0 Gy) as 
shown in Figure 1a. However, for single dose of 150 dan 175 Gy irradiation treatment there was the 
extremely low number of parasites detected in the blood of mouse during observation days as 
evidenced by impaired parasite development, even though they have grown up less than 10% at the 
end of the experiment.  The exception is for 200 Gy irradiation, of which the parasites were still 
grown up to more than 50% at day 40 post-infection (Figure 1b).  
Irradiation was proven to effectively inhibit the growth of parasites so that the mice had a 
much longer lifetime compared to the non-irradiation group (42 days versus 28 days). Considering the 
forms of parasites during its intraerythrocytic stage, at early days (day 7–9), young trophozoites or 
ring forms were mostly observed; on the subsequent days, a clear predominance of a parasite stage 
was not observed. It is essential to be noted that most of the infected mice survived until day 20 
except all mice in 100+50 Gy that dead at day 16 with clinical signs of cerebral malaria. From day 13 
and afterward, young erythrocyte forms appeared in the peripheral blood of mice and parasitized red 
blood cells were getting larger (Figure 2). It is well known that the stages of the parasite that most 
sensitive to irradiation are the ring forms and the early trophozoites; whereas late trophozoites are 
relatively not sensitive. The study also showed that the highest resistance parasites are those of 
irradiated at a time of transition from the late trophozoite and schizont to young ring forms.  
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Figure 1. The fluctuation of parasitemia in mice blood on days post injection of P. berghei irradiated with (a) 




















Figure 2. The microscopic views of parasitized red blood cells as a ring (a), young trophozoite (b), trophozoite 
(c), schizonts (d) forms in mouse body on day 9 post inoculated with 100+50 Gy irradiated P. berghei. 





Malaria parasites are found in every terrestrial habitat on all the warm continents of the world. 
Although research has contributed significantly in the understanding of immunity towards malaria, 
there are still considerable gaps in the knowledge (Tizifa et al., 2018), mainly, similar with the tasks of 
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of malaria vaccines is still one of the primary goals of tropical diseases research. In this article, it is 
provided the first study on growth and examine the infectivity alterations in intraerythrocytic P. berghei 
treated with fractionated doses of γ-radiation to produce vaccine materials. Most tissues show a 
sparing effect of dose fractionation so that each dose for a given endpoint are lower if the dose is 
fractionated or divided into several parts rather than when given as a single dose (ICRP Publication, 
2011; Stewart et al., 2012). But this fractionated dose did not inhibit the growth of the parasite.  
Malaria vaccination attempts with life, attenuated, killed or lysed parasites, as well as, different 
antigenic fractions of the parasite, have been conducted in many parts of the world with varying 
success (Hoffman et al., 2010; Luke and Hoffman, 2003). The development of vaccines in the future 
will not only have to consider all life-cycle stages of the parasite that need to be targeted but will also 
have to take into account which immune responses need to be induced and in which tissue sites 
(Draper et al., 2018; Elsaid et al., 1999).  Development of a successful vaccine against malaria has in 
part, been hampered by the complex life cycle of malaria parasite during which the microorganism 
displays many antigenic forms that elude stage-specific immune responses. The in vitro and in vivo 
experiments of parasite growth inhibitory activity is widely used as a surrogate marker for malaria 
vaccine efficacy (Hoffman et al., 2010; Duncan et al., 2011). 
As seen in the results that a fractionation dose of irradiation did not suppress the parasite 
growth. In the previous study, a dose of gamma rays at 150 and 175 Gy given as single dose were 
effective in suppressing the parasitemia in mice (Darlina, 2011). It has been known that γ-ray causes 
many changes in the parasite which is ranged between decreasing its ability to cause infection and 
retaining its antigen effect to killing this parasite by using these high doses of irradiation and given at 
once (Cockburn et al., 2010). 
This experimental focused on the infectivity of parasites that were irradiated with doses that 
were fractionated. Fractionation is a method for curing cancer using radiation therapy. When the total 
dose of radiation is divided into several smaller doses and for several times, there are 
fewer toxic effects on healthy cells or fewer number of cells will die. This would maximize the effect 
of radiation on cancer and minimizes the negative side effects on normal cells. Experiments have 
found that if the absorbed dose of radiation increases then the number of survived cells will decrease. 
This is due to self-repair mechanisms which repair the damaged DNA and other macromolecules 
such as proteins. Thus when the total dose of radiation is divided into several smaller doses, there are 
fewer toxic effects on healthy cells (Alan and Ahmed, 2011; Moding et al., 2013). That is why in this 
experiment the virulence of parasites was still high upon a lower dose of irradiation. This 
phenomenon is not applicable for attenuating parasites. 
As mentioned above, basics of fractionation irradiation are that a dose is divided into several 
fractions (in this experiment only two fractions) that spares normal tissues where there is a repair of 
sublethal damage between dose fractions and repopulation of living cells. As in cancer therapy, 
however, dividing a radiation dose into several fractions would increase damage to the cancer cells, 
giving a chance to reoxygenation of tumor environment and induction of new combination of the 
genetic material of cells into radiosensitive phases of the cell cycle between dose fraction. 
Fractionation also means that there is a prolongation of treatment that reduces early reactions. 
Cell radiobiology is a complex system where the response (radiosensitivity) of cell depends not 
only on the dose and dose rate of radiation but also on some other physical and biological factors 
such as linear energy transfer (LET), relative biological effectiveness (RBE), repair system, 
oxygenation, cell cycle, and dose fractionation. Other agents that given concurrently as modifier or 
radiosensitizer (e.g. chemoradiotherapy) is also another factor. It is important to be aware of basic 
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radiobiological models which can be used to describe the effects of radiation dose and fractionation. 
In this experiment, 5 minutes as the interval time of two fractions of irradiation was assumed not 
affecting the infectivity of parasites but rather the lower dose delivered 2 times that determined their 





In summary, the experimental data showed that fractionated dose of radiation did not 
effectively attenuate the parasites where they were still growing in the blood of mouse, where 100+75 
Gy is more effective compared to 100+50 and 100+100 Gy. Mice injected with irradiated parasites 
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